Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 4;15(1):39.
doi: 10.1186/s13148-023-01452-6.

Clinical advances in epigenetic therapies for lymphoma

Allison C Rosenthal  1 , Javier L Munoz #  2 , J C Villasboas #  3
Affiliations
Review

Clinical advances in epigenetic therapies for lymphoma

Allison C Rosenthal et al. Clin Epigenetics. .

Abstract

Background: Advances in understanding of cancer biology, genomics, epigenomics, and immunology have resulted in development of several therapeutic options that expand cancer care beyond traditional chemotherapy or radiotherapy, including individualized treatment strategies, novel treatments based on monotherapies or combination therapy to reduce toxicities, and implementation of strategies for overcoming resistance to anticancer therapy.

Results: This review covers the latest applications of epigenetic therapies for treatment of B cell, T cell, and Hodgkin lymphomas, highlighting key clinical trial results with monotherapies and combination therapies from the main classes of epigenetic therapies, including inhibitors of DNA methyltransferases, protein arginine methyltransferases, enhancer of zeste homolog 2, histone deacetylases, and the bromodomain and extraterminal domain.

Conclusion: Epigenetic therapies are emerging as an attractive add-on to traditional chemotherapy and immunotherapy regimens. New classes of epigenetic therapies promise low toxicity and may work synergistically with other cancer treatments to overcome drug resistance mechanisms.

Keywords: B cell lymphoma; EZH2 inhibitor; Hodgkin lymphoma; T cell lymphoma.

PubMed Disclaimer

Conflict of interest statement

Allison C. Rosenthal has nothing to disclose. Javier L. Munoz has served as a consultant for Abbvie/Pharmacyclics, ADC Therapeutics, Alexion, Bayer, BeiGene, Bristol Myers Squibb, Debiopharm, Epizyme, Inc, an Ipsen company, Fosunkite, Genmab, Gilead/Kite Pharma, Innovent, Janssen, Juno/Celgene, Karyopharm, Kyowa, Seagen, and Servier; has received research funding from Bayer, Celgene, Genentech, Gilead/Kite Pharma, Incyte, Janssen, Merck, Millennium, Pharmacyclics, Portola, and Seagen; has received honoraria from Curio, Kyowa, OncView, Physicians’ Education Resource, Seagen, and Targeted Oncology; and has served on speakers’ bureaus for Acrotech/Aurobindo, AstraZeneca, Bayer, BeiGene, Celgene/Bristol Myers Squibb, Genentech/Roche, Gilead/Kite Pharma, Kyowa, Pharmacyclics/Janssen, Seagen, and Verastem. J. C. Villasboas has received institutional funds from Epizyme, Inc, an Ipsen company, and acted as a principal investigator on a clinical trial for Epizyme, Inc, an Ipsen company.

Figures

Fig. 1
Fig. 1
Overview of key epigenetic mechanisms and classes of epigenetic therapies
See this image and copyright information in PMC

References

    1. Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of non-Hodgkin's lymphoma. Med Sci. 2021;9. - PMC - PubMed
    1. Hodgkin lymphoma statistics. American Cancer Society Cancer Statistics Center, 2021. Available at: https://cancerstatisticscenter.cancer.org/?_ga=2.108556481.219238712.162.... Accessed 13 Aug 2021.
    1. Survival rates and factors that affect prognosis (outlook) for non-Hodgkin lymphoma. American Cancer Society, 2022. Available at: https://www.cancer.org/cancer/non-hodgkin-lymphoma/detection-diagnosis-s.... Accessed 27 Jan 2023.
    1. Baudino TA. Targeted cancer therapy: the next generation of cancer treatment. Curr Drug Discov Technol. 2015;12:3–20. doi: 10.2174/1570163812666150602144310. - DOI - PubMed
    1. Chemotherapy side effects. National Health Service, 2020. Available at: https://www.nhs.uk/conditions/chemotherapy/side-effects/. Accessed 1 Feb 2023.

Publication types